Puma Biotechnology Community

NasdaqGS:PBYI Community

1 Narratives written by author
0 Comments on narratives written by author
10 Fair Values set on narratives written by author

Puma Biotechnology

AN

AnalystConsensusTarget

Consensus Narrative from 3 Analysts

Alisertib Trials May Expand Market Reach, But NERLYNX's Revenue Decline And Competition Will Challenge Future Earnings

Key Takeaways Expanding NERLYNX's market through strategic collaborations and international launches could significantly boost revenue, especially with recent market entries. Biotech acquisitions and ongoing trials for new drug indications are pivotal for diversifying revenue streams and enhancing long-term earnings.

US$4.33

FV

30.5% undervalued

0.26%

Revenue growth p.a.

0

0

6

1 day ago